Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-03-14
2000-11-14
LeGuyader, John L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 2352, 4353201, A61K 4800
Patent
active
061470554
ABSTRACT:
The present invention relates to plasmids suitable for IL-2 expression, particularly, human IL-2 expression, and related methods.
REFERENCES:
patent: 4738927 (1988-04-01), Taniguchi et al.
patent: 4992367 (1991-02-01), Cullen et al.
patent: 5122458 (1992-06-01), Post et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5229109 (1993-07-01), Grimm et al.
patent: 5250296 (1993-10-01), Ootsu
patent: 5264618 (1993-11-01), Felgner et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5459127 (1995-10-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5641665 (1997-06-01), Hobart et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5703055 (1997-12-01), Felgner et al.
Galanis et al. J. Clin. Oncology, vol. 17, pp. 3313-3323, 1999.
Stuart H. Orkin, and Arno G. Motulsky. "Report and Recommendations of the Panel to Assess the NIH investment in Research on Gene Therapy", Dec. 7, 1995.
Tomlinson et al. J. Controlled Release, vol. 39, pp. 357-372, 1996.
Crystal Science, vol. 270, pp. 404-410, 1995.
Orkin Report and Recommendations of the panel to assess the NIH investment in research on gene therapy, Dec. 7, 1995.
Hanania et al. Am. J. Med., vol. 99, pp. 537-552, Nov. 1995.
Mulligan, Science, vol. 260, pp. 926-932, May 14, 1993.
Vieweg et al. Cancer Invest., vol. 13, pp. 193-201, 1995.
Blaese et al. Scientific American, vol. 276, pp. 111-115, Jun. 1997.
Verma et al. Nature, vol. 389, pp. 239-242, 1997.
Manthorpe et al. Human Gene Therapy, vol. 4, p. 419-431, 1993.
Montgomery et al. DNA and Cell Biology, vol. 12, pp. 777-783, 1993.
San et al. Human Gene therapy, vol. 4, pp. 781-788, 1993.
Berg, D. et al. (1978) In Microbiology [Schelessinger, D. ed.] pp. 13-15 American Society for Microbiology, Washington D.C.
Bolivar, F. et al. (1977) Construction and characterization of new cloning vehicles II. A multipurpose cloning system. Gene 2:95-113.
Chapman, B. et al. (1991) Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Research 19(14):3979-3986.
Cullen, B. et al. (1988) Expression of a cloned human interleukin-2 cDNA is enhanced by the substitution of a heterologous mRNA leader region. DNA 7(9) 645-650.
Gansbacher, B. et al. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172:1217-1224.
Gansbacher, B. et al. (1992) Retroviral gene transfer induced constitutive expression of interleukin-2-or interferon . . . Blood 80(11):2817-2825.
LaFemina, R. et al. (1980) Structural organization of the DNA molecules from human cytomegalovirus. Animal Virus Genetics 39-55.
Lewin, R. (1987) When does not homology mean something else. Science 237:1570.
Manthorpe, M., et al. (1993) Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. Human Gene Therapy 4:419-431.
Margalith, M., et al. (1995) VCL1102: A plasmid DNA vector to effect high levels of IL-2 expression in vivo. Journal of Cellular Biochemistry Supplement 21A, see abstract C6-534.
Montogomery, D., et al. (1993) Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA and Cell Biology 12(9): 777-783.
Nabel, G., et al. (1994) Immunotherapy for cancer by direct gene transfer into tumors. Human Gene Therapy 5:57-77.
Nabel, G., et al. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl. Acad. Sci. 90:11307-11311.
Oka, A. et al. (1981) Nucleotide sequence of the kanamycin resistance transposon Tn903. J. Mol. Biol. 147:217-226.
O'Quigley, J. et al. (1991) Methods for dose finding studies in cancer clinical trials: a review and results of a monte carlo study. Statistics in Medicine 10:1647-1664.
O'Quigley, J. et al. (1990) Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46:33-48.
Orkin, S., et al. Report and recommendations of the panel to assess the NIH investment in research on gene therapy. Dec. 7, 1995.
Parker, S., et al. (1994) Direct delivery of cytokine genes into tumors for cancer immunotherapy. Journal of Cellular Biochemistry Supplement 18A, see abstract DZ 414.
Plautz, G., et al. (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc. Natl. Acad Sci. 90:4645-4649.
Reeck, G.R., et al. (1987) Homology in proteins and nucleic acids: a terminology muddle and a way out of it. Cell 50:667.
San, H., et al. (1993) Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Human Gene Therapy 4:781-788.
Storer, B. (1989) Design and analysis of phase I clinical trial. Biometrics 45:925-937.
Vile, R.G., and Hart, I.R. (1994) Targeting of cytokine gene expression to malignant melanoma cell using tissue specific promoter sequences. Annals of Oncology 5 (Suppl 5):S59-S65.
Wardley, R., et al. (1992) The use of feline herpesvirus and baculovirus as vaccine vectors for the gag and env genes of feline leukaemia virus. Journal of General Virology 73:1811-1818.
Hobart Peter M.
Khatibi Shirin
Margalith Michal
Parker Suezanne E.
LeGuyader John L.
Vical Incorporated
Wilson Michael C.
LandOfFree
Cancer treatment method utilizing plasmids suitable for IL-2 exp does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cancer treatment method utilizing plasmids suitable for IL-2 exp, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancer treatment method utilizing plasmids suitable for IL-2 exp will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065527